Companies · Other
SAN FRANCISCO · CA, USA · Other · founded 2012 · http://medisas.com
Diligence memoA one-page analyst read on Medisas, Inc. — recommendation, valuation, rhythm, risks.→Medisas, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Medisas, Inc. is one of 25015 Other companies tracked from SAN FRANCISCO, CA, USA, on record since 2012. By capital raised it ranks in the upper tier (ahead of 78% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Medisas builds workflow & collaboration software for hospitals.
Healthcare is broken and underserved by technology. Hospital software is too complicated, too convoluted, and too disconnected. Doctors and nurses spend more time clicking through prompts than checking in on patients, and the quality of care suffers as a result. We're going to change that, and have been able to do so for the care teams of half a million patients and counting.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 25015 companies in Other. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 78% of sector peers (real $). Modeled value above 87% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #105 of 707.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Hogsalt Investors Llc | Series A | $15.0M | $227.0M | 2.59× |
| Fanchise League Co LLC | Series A | $16.1M | $227.0M | 2.59× |
| CannCare, Inc | Series A | $15.0M | $227.0M | 2.59× |
| Baba Joe Diamond Ventures Us Inc. | Series A | $15.0M | $227.0M | 2.59× |
| Instapage, Inc. | Series A | $18.0M | $227.0M | 2.59× |
| Genie Enterprises, Ltd | Series A | $15.0M | $227.0M | 2.59× |
| ACM Research, Inc. | Series A | $15.0M | $227.0M | 2.59× |
| Cardinal Memorial Ultimate Holdings, Llc | Series A | $15.0M | $227.0M | 2.59× |
| Qq Utah 3, Llc | Series A | $15.0M | $227.0M | 2.59× |
| Mina Mar Corp | Series A | $15.0M | $227.0M | 2.59× |
| PASSADO Co Ltd | Series A | $15.0M | $227.0M | 2.59× |
| Tatcha LLC | Series A | $21.3M | $227.0M | 2.59× |
| Medisas, Inc. this company | Series A | $10.6M | $160.3M | 1.83× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $10.6M | 2016-12-01 | $48.1M | $160.3M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Keith Rabois | — | 24 other | 2016-12 |
| Gautam Sivakumar | — | — | 2016-12 |
Medisas, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Milo.Com Inc. | Other | Series A | $4.0M | $60.9M | network1 shared operator · same sector · same stage |
| Soothe, Inc. | Other | Series A | $10.6M | $160.3M | same sector · same stage |
| NYX, Los Angeles Inc. | Other | Series A | $10.6M | $160.4M | same sector · same stage |
| D2C Brand Holding Company, LLC | Other | Series A | $10.6M | $160.0M | same sector · same stage |
| Impex International Holdings, LLC | Other | Series A | $10.6M | $160.0M | same sector · same stage |
| Myshape Inc | Other | Series A | $10.6M | $159.8M | same sector · same stage |
| Tunity Inc. | Other | Series A | $10.6M | $160.8M | same sector · same stage |
| Frontier Rare Earths Ltd | Other | Series A | $10.6M | $161.0M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Parallel AI agents for healthcare admin | AI / ML | — | — | 75% |
| StarJar Starjar automates inbound document processing workflows for hospitals | Healthtech | — | — | 75% |
| Memora Health Digitize and Automate Complex Care Workflows | Healthtech | — | — | 74% |
| Novoflow AI employees that automate medical operations for clinics. | Healthtech | — | — | 74% |
| Pair Team, Inc. Building the safety net of the future | AI / ML | Series B | $4.2M | 74% |
| YouShift The OS for hospital workforce management | HR / Worktech | — | — | 74% |
| Decoda Health The all-in-one EMR built for med spas and elective care | Healthtech | — | — | 74% |
| Medumo, Inc. We manage patient instructions for hospitals | Healthtech | Seed | $54.5M | 74% |
See where Medisas, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Medisas, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.